0
0
heart
A recent review authored by Hana Poloczková and Jan Krejčí delves into the evidence surrounding the use of lipid lowering therapy in heart failure. Despite recent guidelines for diagnosing and treating acute and chronic heart failure, the significance of hypolipidemic treatment in heart failure remains inconclusive. While some randomized controlled trials did not demonstrate significant mortality benefits of statins in these patients, various meta-analyses and cohort studies hint at potential positive effects.
Moreover, discussions have emerged regarding the role of inflammation and the potential influence of hypolipidemics in managing it. The review also highlights the promising efficacy of PCSK9 inhibitors, new lipid lowering drugs, in reducing LDL-cholesterol and preventing atherosclerotic cardiovascular diseases. However, the investigation into the role of PCSK9 inhibitors specifically in heart failure treatment is ongoing.
Presently, the review suggests that while hypolipidemics are not generally recommended in heart failure therapy, exceptions may exist when there’s an alternative indication for their use. This review underscores the ongoing debate and the need for further research to delineate the precise role of lipid lowering therapy in managing heart failure.
